JP2023507603A5 - - Google Patents
Info
- Publication number
- JP2023507603A5 JP2023507603A5 JP2022537646A JP2022537646A JP2023507603A5 JP 2023507603 A5 JP2023507603 A5 JP 2023507603A5 JP 2022537646 A JP2022537646 A JP 2022537646A JP 2022537646 A JP2022537646 A JP 2022537646A JP 2023507603 A5 JP2023507603 A5 JP 2023507603A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- delivery system
- injected
- fas
- cntf compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193448A JP2025020303A (ja) | 2019-12-18 | 2024-11-05 | 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949773P | 2019-12-18 | 2019-12-18 | |
| US62/949,773 | 2019-12-18 | ||
| PCT/US2020/065423 WO2021127052A1 (en) | 2019-12-18 | 2020-12-16 | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193448A Division JP2025020303A (ja) | 2019-12-18 | 2024-11-05 | 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507603A JP2023507603A (ja) | 2023-02-24 |
| JP2023507603A5 true JP2023507603A5 (https=) | 2024-03-26 |
Family
ID=76478085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537646A Pending JP2023507603A (ja) | 2019-12-18 | 2020-12-16 | 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 |
| JP2024193448A Pending JP2025020303A (ja) | 2019-12-18 | 2024-11-05 | 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193448A Pending JP2025020303A (ja) | 2019-12-18 | 2024-11-05 | 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230094423A1 (https=) |
| EP (1) | EP4076495A4 (https=) |
| JP (2) | JP2023507603A (https=) |
| KR (1) | KR20220118499A (https=) |
| CN (1) | CN115119501A (https=) |
| AU (2) | AU2020407072B2 (https=) |
| CA (1) | CA3162324A1 (https=) |
| WO (1) | WO2021127052A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4565596A1 (en) * | 2022-08-05 | 2025-06-11 | ONL Therapeutics, Inc. | Peptide compositions and methods of use |
| EP4565595A2 (en) * | 2022-08-05 | 2025-06-11 | ONL Therapeutics, Inc. | Peptide compositions and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
| IT1288388B1 (it) * | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
| JP2003522160A (ja) * | 2000-02-11 | 2003-07-22 | ジェンベク、インコーポレイティッド | 眼関連疾患の治療のための遺伝子治療 |
| EP1737483A2 (en) * | 2004-04-23 | 2007-01-03 | University of Pittsburgh of the Commonwealth System of Higher Education | Cell death modulation via antagonists of fasl and fas activation |
| US8592374B2 (en) * | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
| CA2722971C (en) * | 2008-05-09 | 2019-05-07 | Qlt Plug Delivery, Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| WO2010102052A2 (en) * | 2009-03-03 | 2010-09-10 | The Regents Of The University Of Michigan | Methods of inhibiting photoreceptor apoptosis |
| CN104640568B (zh) * | 2012-07-18 | 2016-10-19 | 阿珀吉尼科斯股份公司 | 用于治疗mds的cd95信号传导途径的抑制剂 |
| US10508134B2 (en) * | 2015-05-01 | 2019-12-17 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| CA2986769A1 (en) * | 2015-05-27 | 2016-12-01 | Neurotech Usa, Inc. | Use of encapsulated cell therapy for treatment of ophthalmic disorders |
| WO2019246141A1 (en) * | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE |
| CN112566622A (zh) * | 2018-06-19 | 2021-03-26 | 细胞疗法有限责任公司 | 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统 |
-
2020
- 2020-12-16 US US17/787,228 patent/US20230094423A1/en active Pending
- 2020-12-16 EP EP20904211.8A patent/EP4076495A4/en active Pending
- 2020-12-16 AU AU2020407072A patent/AU2020407072B2/en active Active
- 2020-12-16 JP JP2022537646A patent/JP2023507603A/ja active Pending
- 2020-12-16 WO PCT/US2020/065423 patent/WO2021127052A1/en not_active Ceased
- 2020-12-16 CN CN202080096136.0A patent/CN115119501A/zh active Pending
- 2020-12-16 KR KR1020227024646A patent/KR20220118499A/ko active Pending
- 2020-12-16 CA CA3162324A patent/CA3162324A1/en active Pending
-
2024
- 2024-11-05 JP JP2024193448A patent/JP2025020303A/ja active Pending
-
2025
- 2025-06-12 AU AU2025204377A patent/AU2025204377A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5009786B2 (ja) | ２ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント | |
| JP6368700B2 (ja) | 選択した組織へ組成物を送達するための材料と方法 | |
| EP2214646B1 (en) | Dendrimers for sustained release of compounds | |
| JP2023507603A5 (https=) | ||
| JP5153340B2 (ja) | 薬剤放出制御組成物および薬剤放出性医療器具 | |
| US20200330377A1 (en) | Biodegradable Polymer Based Implants for Ocular Drug Delivery | |
| JP2015013863A (ja) | 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 | |
| AU2022247731B2 (en) | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease | |
| JP2012509264A (ja) | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 | |
| CN107278151A (zh) | 舒尼替尼制剂及其在治疗青光眼中的使用方法 | |
| Sridhar et al. | Cross-linking of protein scaffolds for therapeutic applications: PCL nanofibers delivering riboflavin for protein cross-linking | |
| JP2006516621A (ja) | 高度に溶解性の薬剤の制御された放出 | |
| JP2025020303A5 (https=) | ||
| JP2017527611A (ja) | 脊髄損傷を有する患者において炎症を阻害するための組成物、及びそれを使用する方法 | |
| US20150148295A1 (en) | Controlled-Released Peptide Formulations | |
| AU2016330924A1 (en) | Compositions for an injectable, in situ forming neuroscaffold and methods of using the same | |
| CN106455579A (zh) | 用于治疗和预防耳鸣的方法和组合物 | |
| CN115734780B (zh) | 可生物降解组合物和植入物 | |
| CN113301886A (zh) | 包被的眼部植入物 | |
| Lee et al. | Advances in biodegradable ocular drug delivery systems | |
| CN120225178A (zh) | 用于稳定性增强的含利拉鲁肽的微针的组合物及其用途 | |
| JP2005132737A (ja) | 埋込型製剤の薬物保持担体 | |
| CN100475190C (zh) | 眼内植入缓释药物 | |
| JP2005145873A (ja) | ペプチド及びタンパク性薬物放出制御剤の調製方法及びその薬物放出制御剤 | |
| NZ774138B2 (en) | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |